{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:40:42Z","timestamp":1772692842518,"version":"3.50.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study examined the association between pre-treatment inflammation, immune cell- and nutrition\/metabolism-related scores, and prognosis of patients with hepatocellular carcinoma (HCC) post-treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study collected clinical data on demographics, pretreatment blood tests, pathology, and follow-up. Key markers included C-reactive protein, albumin, neutrophil and lymphocyte counts, creatinine, bilirubin, international normalized ratio, tumor size and number, alpha-fetoprotein, platelet count, and CD4+\/CD8+ T-cell levels. Disease-free survival (DFS) was calculated from treatment to recurrence. Twelve scores were derived. Kaplan\u2013Meier and univariate Cox analyses identified significant predictors, followed by multivariate Cox models to determine independent risk factors. Logistic regression and receiver operating characteristic (ROC) analyses assessed predictive performance. Scores were grouped as inflammation-, metabolism-, or immune-related to construct nomograms and evaluate C-index values using R software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Except for Gender (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.019), all other clinical characteristics showed no statistically significant differences between the training and validation sets (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;gt; 0.05).Univariate Cox regression showed that pre-albumin (P = 0.01), PNI (P &amp;lt; 0.001), TBS (P = 0.01), ALBI (P &amp;lt; 0.001), PALBI (P &amp;lt; 0.001), and CRAFITY (P &amp;lt; 0.001) were significantly associated with DFS. Multivariate analysis identified PALBI (P = 0.03) and CRAFITY (P = 0.04) as independent predictors. A prognostic model was constructed: Risk score = 0.03903 \u00d7 TBS + 0.79809 \u00d7 PALBI + 0.40881 \u00d7 CRAFITY, stratifying patients into high- and low-risk groups. Kaplan\u2013Meier analysis showed significantly better DFS in the low-risk group (P = 0.001). ROC analysis for 1- and 2-year DFS yielded AUCs of 0.69 and 0.75. Logistic regression confirmed the risk score as a predictor of mortality (P = 0.002, AUC = 0.644). Excluding TBS, the remaining scores were grouped into inflammation-related, nutrition\/metabolism-related, and immune-related categories. Corresponding nomograms showed good calibration, with C-index values of 0.610, 0.581, and 0.575, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pre-treatment PALBI and CRAFITY scores are independent prognostic factors for post-treatment survival among patients with HCC, with inflammation-related scores providing superior predictive value for DFS compared to metabolism- and immune-related scores.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1683412","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:25:47Z","timestamp":1772688347000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a post-treatment prognostic model for hepatocellular carcinoma based on nutritional, immune, and inflammatory scoring systems and REDCap-enabled follow-up"],"prefix":"10.3389","volume":"16","author":[{"given":"Xuemei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengqiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2019.188314","article-title":"Challenges in liver cancer and possible treatment approaches","volume":"1873","author":"Anwanwan","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-017-2806-0","article-title":"Microenvironment of liver regeneration in liver cancer","volume":"23","author":"Li","year":"2017","journal-title":"Chin J Integr Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01246-9","article-title":"The trend of the treatment of advanced hepatocellular carcinoma: combination of immunotherapy and targeted therapy","volume":"25","author":"Dong","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.07.018","article-title":"Heterogeneity of liver cancer and personalized therapy","volume":"379","author":"Li","year":"2016","journal-title":"Cancer Lett"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.joim.2025.06.003","article-title":"Integrated-omics analysis defines subtypes of hepatocellular carcinoma based on circadian rhythm","volume":"23","author":"Li","year":"2025","journal-title":"J Integr Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s43657-023-00136-8","article-title":"A noninvasive approach to evaluate tumor immune microenvironment and predict outcomes in hepatocellular carcinoma","volume":"3","author":"Wu","year":"2023","journal-title":"Phenomics"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2021.01091","article-title":"Conversion therapy and maintenance therapy for primary hepatocellular carcinoma","volume":"15","author":"Zhou","year":"2021","journal-title":"Biosci Trends"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S349426","article-title":"Advances in nanoliposomes for the diagnosis and treatment of liver cancer","volume":"17","author":"Li","year":"2022","journal-title":"Int J Nanomedicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1186\/s12885-023-11629-0","article-title":"Prognostic potential of preoperative circulating tumor cells to predict the early progression recurrence in hepatocellular carcinoma patients after hepatectomy","volume":"23","author":"Lu","year":"2023","journal-title":"BMC Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005538","article-title":"Predicting long-term survival and time-to-recurrence after esophagectomy in patients with esophageal cancer - Development and validation of a multivariate prediction model","volume":"277","author":"Gujjuri","year":"2023","journal-title":"Ann Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-017-3619-3","article-title":"Correlation between postoperative early recurrence of hepatocellular carcinoma and mesenchymal circulating tumor cells in peripheral blood","volume":"22","author":"Wang","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","article-title":"Paradoxical roles of the immune system during cancer development","volume":"6","author":"de Visser","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1134\/S0006297917080016","article-title":"Components of the hepatocellular carcinoma microenvironment and their role in tumor progression","volume":"82","author":"Novikova","year":"2017","journal-title":"Biochem (Mosc)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e8056","DOI":"10.1097\/MD.0000000000008056","article-title":"Inflammation-nutrition scope predicts prognosis of early-stage hepatocellular carcinoma after curative resection","volume":"96","author":"Zhu","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1486","DOI":"10.1097\/MD.0000000000001486","article-title":"Prognostic value of the modified glasgow prognostic score in patients undergoing radical surgery for hepatocellular carcinoma","volume":"94","author":"Ni","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.23736\/S0031-0808.16.03236-5","article-title":"Modified Glasgow prognostic score might be a prognostic factor for hepatocellular carcinoma: a meta-analysis","volume":"59","author":"Chen","year":"2017","journal-title":"Panminerva Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.92","article-title":"A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI)","volume":"106","author":"Pinato","year":"2012","journal-title":"Br J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0202987","DOI":"10.1371\/journal.pone.0202987","article-title":"The prognostic value of prognostic nutritional index in hepatocellular carcinoma patients: A meta-analysis of observational studies","volume":"13","author":"Wang","year":"2018","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1186\/s12885-023-11166-w","article-title":"Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy","volume":"23","author":"Kang","year":"2023","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/JHC.S396433","article-title":"Nomogram based on platelet-albumin-bilirubin for predicting tumor recurrence after surgery in alpha-fetoprotein-negative hepatocellular carcinoma patients","volume":"10","author":"Yang","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0226","DOI":"10.1097\/MD.0000000000010226","article-title":"Preoperative platelet-albumin-bilirubin grades predict the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after liver resection: A retrospective study","volume":"97","author":"Luo","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e24476","DOI":"10.1097\/MD.0000000000024476","article-title":"Prognostic significance of postoperative change of PALBI grade for patients with hepatocellular carcinoma after hepatectomy","volume":"100","author":"Wang","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20761","article-title":"Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis","volume":"12","author":"Cucchetti","year":"2006","journal-title":"Liver Transpl"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/HMER.S9049","article-title":"Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine","volume":"5","author":"Lau","year":"2013","journal-title":"Hepat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000530987","article-title":"Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria","volume":"101","author":"Ohama","year":"2023","journal-title":"Oncology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-21-506","article-title":"Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study","volume":"12","author":"Xin","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14131325","article-title":"Clinical utility of the aMAP score for predicting hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"14","author":"Chaiwiriyawong","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1474456","article-title":"The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12885-023-10686-9","article-title":"Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10535-8","article-title":"Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy","volume":"17","author":"Guan","year":"2023","journal-title":"Hepatol Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e18571","DOI":"10.1097\/MD.0000000000018571","article-title":"Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: A meta-analysis","volume":"99","author":"Wang","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14220","article-title":"The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma","volume":"39","author":"Sanghera","year":"2019","journal-title":"Liver Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-3125","article-title":"Neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers to predict relapse and survival in posthepatectomy HBV-related hepatocellular carcinoma: a meta-analysis and preliminary immune perspective","volume":"10","author":"Zheng","year":"2021","journal-title":"Transl Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PloS Pathog"},{"key":"B37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12981-018-0200-4","article-title":"CD4\/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV","volume":"15","author":"Han","year":"2018","journal-title":"AIDS Res Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1186\/s12885-022-09999-y","article-title":"Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma","volume":"22","author":"Tan","year":"2022","journal-title":"BMC Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00423-023-02869-6","article-title":"Radiographic tumor burden score is useful for stratifying the overall survival of hepatocellular carcinoma patients undergoing resection at different Barcelona Clinic Liver Cancer stages","volume":"408","author":"Li","year":"2023","journal-title":"Langenbecks Arch Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13163961","article-title":"Refining prognosis in chemoembolization for hepatocellular carcinoma: immunonutrition and liver function","volume":"13","author":"M\u00fcller","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e048324","DOI":"10.1136\/bmjopen-2020-048324","article-title":"Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: a systematic review and meta-analysis","volume":"11","author":"Jiang","year":"2021","journal-title":"BMJ Open"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e70352","DOI":"10.1002\/cam4.70352","article-title":"Preoperative inflammatory scores do not accurately predict early recurrence of pancreatic ductal adenocarcinoma after resection: A systematic review and meta \u2026","volume":"13","author":"de Castro e Borges EK","year":"2024","journal-title":"Cancer Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i45.17132","article-title":"Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma","volume":"20","author":"Han","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2023.11.004","article-title":"Hepatocellular carcinoma recurrence: Predictors and management","volume":"7","author":"Abdelhamed","year":"2023","journal-title":"Liver Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"8670","DOI":"10.1038\/s41598-022-12518-5","article-title":"A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection","volume":"12","author":"Wang","year":"2022","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2019.11.009","article-title":"Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection","volume":"22","author":"Dong","year":"2020","journal-title":"HPB (Oxford)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040747","article-title":"Synergistic impact of alpha-fetoprotein and tumor burden on long-term outcomes following curative-intent resection of hepatocellular carcinoma","volume":"13","author":"Tsilimigras","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e0216173","DOI":"10.1371\/journal.pone.0216173","article-title":"Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study","volume":"14","author":"Lee","year":"2019","journal-title":"PloS One"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S439660","article-title":"Prognosis prediction of CRAFITY score in HCC undergoing TACE combined with PD-(L)1 inhibitors and molecular targeted therapy","volume":"10","author":"Hu","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030641","article-title":"Inflammatory mechanisms of HCC development","volume":"12","author":"Refolo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142549","article-title":"Decoding the prognostic significance and therapeutic implications of inflammation-based scores in hepatocellular carcinoma: A comprehensive review","volume":"16","author":"Kotsifa","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e2784","DOI":"10.1097\/MD.0000000000002784","article-title":"A novel and validated inflammation-based score (IBS) predicts survival in patients with hepatocellular carcinoma following curative surgical resection: A STROBE-compliant article","volume":"95","author":"Fu","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cells14070488","article-title":"The role of inflammation in cancer: mechanisms of tumor initiation, progression, and metastasis","volume":"14","author":"Nishida","year":"2025","journal-title":"Cells"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137191","article-title":"Inflammatory response in the pathogenesis and treatment of hepatocellular carcinoma: A double-edged weapon","volume":"25","author":"Galasso","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41420-023-01356-7","article-title":"Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy","volume":"9","author":"Zheng","year":"2023","journal-title":"Cell Death Discov"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10707-0","article-title":"Inflammation of the liver, HCC development and HCC establishment","volume":"18","author":"Kanda","year":"2024","journal-title":"Hepatol Int"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604997","article-title":"Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer","volume":"100","author":"Moyes","year":"2009","journal-title":"Br J Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100347","article-title":"ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma","volume":"3","author":"Demirtas","year":"2021","journal-title":"JHEP Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030753","article-title":"Prognostic prediction for patients with hepatocellular carcinoma and ascites: role of albumin-bilirubin (ALBI) grade and easy (EZ)-ALBI grade","volume":"15","author":"Liao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1267870","article-title":"Inflammation-related prognostic markers in resected hepatocellular carcinoma","volume":"13","author":"Giannone","year":"2023","journal-title":"Front Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12889-025-21423-1","article-title":"Association between systemic immune-inflammation index and the risk of all-cause, cancer and non-cancer mortality in the general population: results from national health and nutrition examination survey 2005-2018","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Public Health"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1683412\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:25:48Z","timestamp":1772688348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1683412\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":63,"alternative-id":["10.3389\/fonc.2026.1683412"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1683412","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"article-number":"1683412"}}